CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 27, Issue 12, Pages 997-1005
Publisher
Informa UK Limited
Online
2018-10-31
DOI
10.1080/13543784.2018.1543399
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease PatientsHighlights
- (2018) Andreas Gille et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- THE SAFETY AND TOLERABILITY OF MULTIPLE DOSE ADMINISTRATION OF CSL112, AN INTRAVENOUS FORMULATION OF PLASMA-DERIVED APOA-I, AMONG SUBJECTS WITH MODERATE RENAL IMPAIRMENT AFTER ACUTE MYOCARDIAL INFARCTION
- (2018) C. Michael Gibson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study
- (2018) Paul A. Gurbel et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- HDL Mimetics Infusion and Regression of Atherosclerosis: Is It Still Considered a Valid Therapeutic Option?
- (2018) I. Karalis et al. Current Cardiology Reports
- Impaired Renal Function on Cholesterol Efflux Capacity, HDL Particle Number, and Cardiovascular Events
- (2018) Shahzad Chindhy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Apolipoprotein A-I Infusion Therapies for Coronary Disease
- (2018) Daniel J. Rader JAMA Cardiology
- Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial
- (2018) Stephen J. Nicholls et al. JAMA Cardiology
- Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial
- (2018) Stephen J. Nicholls et al. JAMA Cardiology
- HDL Cholesterol Efflux Capacity and Cardiovascular Events in Patients With Chronic Kidney Disease
- (2017) Lucie Bauer et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction
- (2016) C. Michael Gibson et al. AMERICAN HEART JOURNAL
- Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial InfarctionClinical Perspective
- (2016) C. Michael Gibson et al. CIRCULATION
- Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112Novelty and Significance
- (2016) Svetlana A. Didichenko et al. CIRCULATION RESEARCH
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice
- (2016) Massimo F. Piepoli et al. EUROPEAN HEART JOURNAL
- HDL Particle Size Is a Critical Determinant of ABCA1-Mediated Macrophage Cellular Cholesterol ExportNovelty and Significance
- (2015) Xian-Ming Du et al. CIRCULATION RESEARCH
- 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
- (2015) Marco Roffi et al. EUROPEAN HEART JOURNAL
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Infusion of Reconstituted High‐Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial
- (2015) Pierluigi Tricoci et al. Journal of the American Heart Association
- CSL112 Enhances Biomarkers of Reverse Cholesterol Transport After Single and Multiple Infusions in Healthy Subjects
- (2014) Andreas Gille et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Reconstituted High-Density Lipoprotein Therapies
- (2014) Ali Javaheri et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
- (2014) Ezra A. Amsterdam et al. CIRCULATION
- Humans With Atherosclerosis Have Impaired ABCA1 Cholesterol Efflux and Enhanced High-Density Lipoprotein Oxidation by Myeloperoxidase
- (2014) Baohai Shao et al. CIRCULATION RESEARCH
- High-Density Lipoprotein and Atherosclerosis Regression
- (2014) Jonathan E. Feig et al. CIRCULATION RESEARCH
- Alteration of HDL functionality and PON1 activities in acute coronary syndrome patients
- (2014) Abdelghani Bounafaa et al. CLINICAL BIOCHEMISTRY
- Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial
- (2014) J.-C. Tardif et al. EUROPEAN HEART JOURNAL
- Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events
- (2014) Anand Rohatgi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel Formulation of a Reconstituted High-Density Lipoprotein (CSL112) Dramatically Enhances ABCA1-Dependent Cholesterol Efflux
- (2013) Svetlana Diditchenko et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- A multiple ascending dose study of CSL112, an infused formulation of ApoA-I
- (2013) Rachael Easton et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
- (2012) Benjamin F Voight et al. LANCET
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
- (2012) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Prospective Natural-History Study of Coronary Atherosclerosis
- (2011) Gregg W. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now